Ratings ChromaDex Corporation

Equities

CDXC

US1710774076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
3.69 ^USD	-2.64%		-4.16%	+158.04%

Apr. 09	Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating	MT
Mar. 11	HC Wainwright Adjusts Price Target on ChromaDex to $6 From $5, Maintains Buy Rating	MT

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the past twelve months, EPS forecast has been revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company sustains low margins.
With an expected P/E ratio at 922.5 and 64.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company is highly valued given the cash flows generated by its activity.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CHROMADEX CORPORATION	+158.04%	286M	C-
IQVIA HOLDINGS INC.	-1.42%	41.35B	B
LONZA GROUP AG	+42.15%	40.38B	A
MODERNA, INC.	+1.97%	39.05B	B-
CELLTRION, INC.	-14.19%	26.67B	C
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B	C+
MEDPACE HOLDINGS, INC.	+21.36%	11.6B	C+
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes